Comment on “ COVID ‐19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action”
Cutaneous manifestation of COVID‐19 reporting from Middle‐Eastern countries: A point of view!
Cutaneous and Allergic reactions due to COVID‐19 vaccinations: A review
ABSTRACT Introduction The pandemic caused by the novel coronavirus disease 2019 (COVID‐19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable strategy to end the pandemic, despite the slower‐than‐hoped‐for rollout, particularly for low‐to‐middle‐income countries, and the uncertain duration of protection afforded by vaccination. The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS‐CoV‐2 vaccines. This protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to Acute R…
Low dose of isotretinoin: A comprehensive review
Isotretinoin is a first-generation retinoid initially approved for the treatment of severe cases of acne vulgaris (nodulocystic acne). Because of its broad anti-inflammatory and immunomodulatory properties, it has been used beyond its initial approval in a myriad of other indications. Adverse effects of isotretinoin vary from xerosis to teratogenicity. Herein, we reviewed the literature, through date-unlimited PubMed search, from inception till December 2019, using the following search terms: "low-dose isotretinoin" and "dermatology," "isotretinoin and safety," "isotretinoin, off-label uses," "isotretinoin and male fertility," "isotretinoin, iPLEDGE system," aiming to deliver a therapeutic …
Sexually transmitted COVID‐19
Omalizumab and COVID-19 treatment: Could it help?
Comment on “Androgens and women: COVID‐19 outcomes in women with acne vulgaris, polycystic ovarian syndrome, and hirsutism”
Systemic isotretinoin therapy in the era of COVID‐19
Could isotretinoin be a protective agent against COVID-19?: A dermatologist perspective.
Being a "trending" unique treatment for moderate-to-severe acne, isotretinoin (13-cis retinoic acid) (ISO) is currently considered by experts the first line treatment even for mild acne, unless there is an absolute contraindication. ISO was identified, among other retinoids, to inhibit SARS-CoV-2 replication in Vero E6 cells. Shoemark et al.1.